
Baxter (BAX) Stock Forecast & Price Target
Baxter (BAX) Analyst Ratings
Bulls say
Baxter International has demonstrated positive momentum in its Healthcare Systems & Technologies segment, with year-over-year sales growth of approximately 6% in 1Q25 and 2% in 2Q25, indicating consistent demand for its medical supplies and equipment. The company's strategic acquisition of Hillrom has expanded its portfolio, enhancing its market position in hospital-focused offerings, complemented by recent pricing initiatives expected to contribute approximately 100 basis points of sales growth through 2025. While there are uncertainties regarding the sustainability of this growth as comparisons normalize in 2026, Baxter's robust performance and expanded product capabilities create a favorable outlook for the company.
Bears say
Baxter International's recent performance in 2Q25 showed a decline in sales, margins, and earnings per share (EPS), all falling short of consensus expectations, reflecting ongoing challenges for the company. Operational missteps experienced between 2021 and 2023 have contributed to mixed quarterly results and downward revisions in guidance, indicating deeper issues within the organization. Additionally, a notably low gross margin of 40.7%, compared to the consensus of 42.7%, coupled with an operating margin of 15.1%, which was over 100 basis points below expectations, signals significant inefficiencies and unfavorable product mix concerns.
This aggregate rating is based on analysts' research of Baxter and is not a guaranteed prediction by Public.com or investment advice.
Baxter (BAX) Analyst Forecast & Price Prediction
Start investing in Baxter (BAX)
Order type
Buy in
Order amount
Est. shares
0 shares